{
    "clinical_study": {
        "@rank": "23527", 
        "arm_group": [
            {
                "arm_group_label": "Fed Cohort", 
                "arm_group_type": "Other", 
                "description": "PBT2 250 mg is administered orally following a high fat breakfast"
            }, 
            {
                "arm_group_label": "Fasted Cohort", 
                "arm_group_type": "Other", 
                "description": "PBT2 250 mg is administered orally following a 10 hour period of fasting"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose\n      of PBT2 administered to healthy volunteers in the presence and absence of food."
        }, 
        "brief_title": "Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "The study will be conducted in 2 dosing periods, with participants being randomised to\n      receive PBT2 250 mg with or without food in the first dosing period, followed by a 7 day\n      washout period before receiving the opposite fed/fasted condition to that allocated in the\n      first dosing period. Pharmacokinetic samples will be collected during each dosing period,\n      along with safety monitoring assessments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or females with a BMI between 19 and 30kg/m2\n\n          -  No clinically significant abnormalities\n\n        Exclusion Criteria:\n\n          -  Exposure to medications/drugs that interfere with metabolism of PBT2 including drugs\n             that inhibit or induce CYP1A2)\n\n          -  Use of caffeine-containing beverages, supplements or alcohol within 72 hours of study\n             entry\n\n          -  Significant history of depression or other psychiatric illness\n\n          -  Surgical or medical conditions which could significantly alter drug absorption,\n             distribution, metabolism or excretion\n\n          -  unable to swallow capsules"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107313", 
            "org_study_id": "PBT2-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fed Cohort", 
                "description": "PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.", 
                "intervention_name": "Fed Cohort PBT2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fasted Cohort", 
                "description": "PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food", 
                "intervention_name": "Fasted Cohort PBT2", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "email": "S.Mason@nucleusnetwork.com.au", 
                "last_name": "Sue Mason", 
                "phone": "+613 9076 8900"
            }, 
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Centre for Clinical Studies - Nucleus Network"
            }, 
            "investigator": {
                "last_name": "Jason Lickliter, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Single Centre, Randomised, 2 Period Crossover Study to Determine the Effect of Food on the Pharmacokinetic Profile of a Single Dose of PBT2 Administered Orally to Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Prana Biotechnology", 
            "last_name": "Caroline Herd", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area Under the Concentration-Time Curve (AUC 0-t)", 
            "safety_issue": "No", 
            "time_frame": "prior to the initial doses on day 1 and 8 and then 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 5, 5.5, 6, 8,10,12,16, 24, 30, 36, 48 hours post each dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107313"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 15 days after the first dose of PBT2"
        }, 
        "source": "Prana Biotechnology Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prana Biotechnology Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}